ClinicalTrials.gg
CompletedNCT05429775Updated Jun 23, 2022

In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects

A Phase 1 interventional study of Budesonide in Healthy Volunteers, sponsored by Sandoz. Completed at 1 site in United Kingdom. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Dec 2018, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
30 Years to 65 Years
Sex
All
01

Study summary

This is a single centre, open-label, sequential, single dose 4-period crossover, scintigraphic imaging study in healthy male and non-pregnant, non-lactating female subjects.

Read the detailed description

Subjects will be screened for eligibility to participate in the study up to 28 days before dosing. For each treatment period, subjects will be admitted to the clinical unit on the evening prior to IMP administration (Day -1) and will fast overnight for a minimum of 8 h. On the morning of Day 1, subjects will receive IMP in the fasted state and will remain on site until 24 h post-dose. Following Period 2, there will be an interim analysis and review of safety and scintigraphy data from dosed regimens in order to determine which formulations will be used in subsequent periods. A follow-up phone call will take place 3 to 5 days post-final dose to ensure the ongoing wellbeing of the subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

First submitted before Sandoz left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females aged 30 to 65 years
  • 18.0 to 32.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Budesonide: Formulation 1

    single dose of 2 mg oral suspension formulation 1 administered orally under fasting conditions

    Drug: Budesonide

  • Experimental
    Budesonide: Formulation 2

    single dose of 2 mg oral suspension formulation 2 administered orally under fasting conditions

    Drug: Budesonide

  • Experimental
    Budesonide: Formulation 3

    single dose of 2 mg oral suspension formulation 3 administered orally under fasting conditions

    Drug: Budesonide

  • Experimental
    Budesonide: Formulation 4

    single dose of 2 mg oral suspension formulation 4 administered orally under fasting conditions

    Drug: Budesonide

Interventions

  • single dose of 2 mg oral suspension formulation administered orally under fasting conditions

06

What researchers measure

Primary outcomes

  1. Total oesophageal transit time

    A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.

    Time frame: During procedure

  2. Time at which 10% radiolabel administered has arrived in the oesophagus from the mouth (T10%) (min)

    A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.

    Time frame: During procedure

  3. Time at which 50% radiolabel administered has arrived in the oesophagus from the mouth (T50%) (min)

    A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.

    Time frame: During procedure

  4. Time at which the amount of radiolabel present in the oesophagus peaks (Tmax) (min)

    A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.

    Time frame: During procedure

  5. Time at which 90% of the radiolabel present at Tmax has left the oesophagus (T90%) (min)

    A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.

    Time frame: During procedure

  6. Total amount of radiolabel present in the oesophagus and the three regions over time

    A comparison of the in vivo oesophageal transit times of budesonide suspension formulations will be determined using scintigraphic methods.

    Time frame: During procedure

Secondary outcomes

  1. Number of adverse events

    Number of adverse events will be provided to get additional information on the safety and tolerability of budesonide suspension formulations after oral administration.

    Time frame: throughout the study, approximately 13 weeks

07

Study locations

1 site
  • Sandoz Investigative Site
    Nottingham, England NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Jan 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2022
First posted
Jun 23, 2022
StartActual
Dec 26, 2018
Primary completionActual
Jan 29, 2019
CompletionActual
Jan 29, 2019
Last update
Jun 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05429775
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Jun 23, 2022
Start date
Dec 26, 2018
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Last update
Jun 23, 2022

Study contacts

Sandoz
study director · Sandoz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion